Dr. Rosalia Rutter

In this year's Scientific Knowledge Exchange, Prof. Dr. Reinhard Dummer, University Hospital of Zurich, and Prof. Dr. Olivier Michielin, University Hospital of Lausanne, discuss ASCO 2019’s news in melanoma research and therapy.

PD Dr. Richard Cathomas, Kantonsspital Chur, Graubünden, talks about the most interesting studies in genitourinary cancers presented at this year's ASCO.

In this Breakfast Brief Prof. Dr. Solange Peters, Central University Hospital (CHUV) in Lausanne, presents new and noteworthy trials dominating current discussions in lung cancer.

PD DDr. Sacha Rothschild, University Hospital Basel, comments on this year's head and neck cancer studies, as well as lung cancer trials.

Ado-trastuzumab emtansine represents a feasible treatment strategy for patients with advanced SGT and shows early evidence of activity in a subset of patients.

Treatment with the next-generation FLT3 inhibitor gilteritinib improved survival of patients with relapsed/refractory acute myeloid leukemia (AML) compared to standard chemotherapy.

Umbralisib, a small-molecule inhibitor that targets PI3K-delta, is safe and efficacious for patients with relapsed/refractory marginal zone lymphoma. This an interim analysis of the phase II clinical trial UNITY-NHL shows.

In this video interview, Prof. Dr. Olivier Michielin, Central Univercity Hospital (CHUV) in Lausanne, reviews the use of biomarkers and discusses the future challenges and opportunities in this field of research.